Skip to product information
1 of 1

FDA ANDA 206873, GLATIRAMER ACETATE, SYNTHON PHARMS INC, 09/25/2024

FDA ANDA 206873, GLATIRAMER ACETATE, SYNTHON PHARMS INC, 09/25/2024

Regular price $622.69 USD
Regular price Sale price $622.69 USD
Sale Sold out

Content: Summary Basis of Approval for the Glatiramer Acetate Injection, 40 mg/mL application #A206873, approved on September 25, 2024.

ANDA: 206873
Company: SYNTHON PHARMS INC
Drug Name: GLATIRAMER ACETATE
Active Ingredients: GLATIRAMER ACETATE
Strength: 40MG/ML
Dosage Form/Route: INJECTABLE;SUBCUTANEOUS
Action Date: 09/25/2024
Marketing Status: Prescription
Submission Classification: ORIG-1

202 Pages

View full details
FOIA Pro

This drug has a lot more FDA history than one product page can show

FOIA Pro gives you full-text search across 70,000+ FDA FOIA records, from 2020 through today, plus a monthly monitor tracking new requests as they close.
  • Full-text search across every FDA FOIA log since 2020
  • Warning letters, approval records, and correspondence in one place
  • Monthly FDA FOIA Monitor newsletter, included
  • Cancel anytime, monthly or annual billing
Get FOIA Pro
Live search · FOIA database
Searching related FDA records…
ClosedTypeSubjectOutcome